Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Liabilities (2016 - 2025)

Corcept Therapeutics' Total Liabilities history spans 10 years, with the latest figure at $188.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 17.32% year-over-year to $188.8 million; the TTM value through Dec 2025 reached $188.8 million, up 17.32%, while the annual FY2025 figure was $188.8 million, 17.32% up from the prior year.
  • Total Liabilities for Q4 2025 was $188.8 million at Corcept Therapeutics, down from $191.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $191.7 million in Q3 2025 and bottomed at $41.6 million in Q1 2021.
  • The 5-year median for Total Liabilities is $105.5 million (2023), against an average of $105.9 million.
  • The largest annual shift saw Total Liabilities dropped 0.92% in 2021 before it skyrocketed 120.97% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $47.9 million in 2021, then soared by 70.15% to $81.6 million in 2022, then skyrocketed by 40.72% to $114.8 million in 2023, then skyrocketed by 40.2% to $161.0 million in 2024, then grew by 17.32% to $188.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Total Liabilities are $188.8 million (Q4 2025), $191.7 million (Q3 2025), and $165.9 million (Q2 2025).